Issue: 2017 > May > case report

A case of rivaroxaban-associated acute tubulointerstitial nephritis



CASE REPORT
R.C. Monahan, M.M. Suttorp, B.A.Th.F. Gabreƫls
AbstractFull textPDF

Abstract

Rivaroxaban is a direct oral anticoagulant that is prescribed for the prevention and treatment of thromboembolisms. Rivaroxaban is cleared renally and a common side effect (1-10%) is renal impairment of unknown pathophysiology. We are the first to describe a case of biopsy-proven acute tubulointerstitial nephritis, most likely caused by rivaroxaban.